Replies to post #148647 on Elite Pharmaceuticals Inc (ELTP)

[Eltp]

Great first post, welcome aboard. Good to read all these deep DD and analysis

[dr_lowenstein]

Hmmmmmmmmmm, I have spoken with literally hundreds of pain management docs that routinely prescribe ER opioids and find them quite useful, particularly in chronic pain conditions.Also they all had prescribed Embeda and are now prescribing again. It may be a biased sample as none of them pay much attention to the stock market. Makes one wonder....... LOL LOL

[toofun]

Welcome WeeZuhl, someone who remarked that they spoke to hundreds of pain management doctors should probably know the prescribing habits of internists are different than pain specialists. The use of short acting opiates in general practice is far more common especially since our legislators have started to meddle with who can/should do what with their patients.

[mrwrn2010]

Great post, glad to have you aboard. I also believe ELI-200 is Oxy, perhaps IR as you state. It is the only drug mentioned in the trial description. This is a huge development indeed as I had expected Morphine/Naltrexone to be the first ART drug to launch. Good luck to you.

[Money_Tree]

Yea I also agree it will be an oxy product and I've said that for a while now it could be the once a day oxy which would've been the only once a day on the market if it wasn't for Purdue recently. Hard to believe their 'flagship' product would be morphine when their tech is modular to the point they can manufacture any opioid so why not shoot for the best moneymaking pain drug and we all know oxy is where most of the money is even though competition is growing there.

Also take a simplistic approach, 200 is once a day, 201 is twice a day, I'm sure they would like to keep it organized in a nice number pattern. Just my .02